Success Stories: NIW Approval Was Secured for a Director in the Clinical Epidemiology Field From South Korea in Just a Week, and No RFE Was Issued
Client’s Testimonial:
“Thank you very much! Wonderful news!”
On January 5th, 2024, we received another EB-2 NIW (National Interest Waiver) approval for a Director of Life Science Success in the Field of Clinical Epidemiology (Approval Notice).
General Field: Clinical Epidemiology
Position at the Time of Case Filing: Director of Life Science Success
Country of Origin: South Korea
State of Residence at the Time of Filing: California
Approval Notice Date: January 5th, 2024
Processing Time: 7 days (Premium Processing Requested)
Case Summary:
Recently, an EB-2 National Interest Waiver (NIW) petitioner from South Korea was successfully represented by the North America Immigration Law Group. The client was a director in the field of clinical epidemiology whose work involved conducting epidemiological studies surrounding individuals who are at risk for kidney and cardiovascular diseases to improve patient health outcomes. We deduced that among other applications, her research seemed to be relevant to advancing global health policies by clarifying the epidemiological terrain and tackling common challenges associated with kidney and cardiovascular diseases.
Thus, we decided to take on her case, with the intention of showcasing her accomplishments. She has an advanced degree; a Ph.D. in epidemiology, and she is a member of the profession. Additionally, her research qualifies for a national interest waiver under the criteria outlined in the Matter of DHANASAR because it is an undertaking with significant quality and national significance.
In addition, we highlighted that our client’s intended research work is of great importance because it addresses several pressing challenges facing public health. To further support this petition, we listed her successful track record and significant influence on the field.
- Her research has published 21 peer-reviewed journal articles (9 of them first-authored or co-first-authored), 11 abstracts (5 of them first-authored), and 1 preprint in no less than 14 highly ranked peer-reviewed journals.
- Her published papers altogether accumulated 662 citations from many other experts, proving that she has had a major influence on other scholars’ understanding of topics in her chosen field.
- In addition, she has been invited to conduct peer reviews and she has completed at least 1 review to date due to her knowledge and expertise in investigating cardiovascular disease risk, progression, and outcomes among patients with chronic kidney disease, end-stage renal disease, and kidney transplantation.

